Halozyme Therapeutics, Inc. (NASDAQ:HALO) Receives $73.00 Consensus Price Target from Analysts

Halozyme Therapeutics, Inc. (NASDAQ:HALO) has been given a consensus recommendation of “Hold” by the twelve ratings firms that are presently covering the company, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $73.00.

Several equities research analysts have issued reports on the stock. Wall Street Zen cut shares of Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 5th. Morgan Stanley lifted their target price on shares of Halozyme Therapeutics from $75.00 to $80.00 and gave the stock an “overweight” rating in a research note on Monday, August 18th. Benchmark lifted their target price on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a research note on Wednesday, September 24th. Leerink Partners raised shares of Halozyme Therapeutics from an “underperform” rating to a “market perform” rating and set a $70.00 target price on the stock in a research note on Tuesday. Finally, JPMorgan Chase & Co. boosted their price target on shares of Halozyme Therapeutics from $60.00 to $63.00 and gave the company a “neutral” rating in a research report on Thursday, August 7th.

Insider Activity

In other news, CFO Nicole Labrosse sold 20,000 shares of the business’s stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $75.71, for a total transaction of $1,514,200.00. Following the transaction, the chief financial officer owned 24,306 shares of the company’s stock, valued at approximately $1,840,207.26. The trade was a 45.14% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Bernadette Connaughton sold 4,000 shares of the business’s stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $73.68, for a total transaction of $294,720.00. Following the transaction, the director directly owned 46,952 shares in the company, valued at approximately $3,459,423.36. The trade was a 7.85% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 108,227 shares of company stock valued at $7,779,595. 2.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Wealth Preservation Advisors LLC acquired a new position in Halozyme Therapeutics in the first quarter valued at about $32,000. Newbridge Financial Services Group Inc. acquired a new position in Halozyme Therapeutics in the second quarter valued at about $32,000. SVB Wealth LLC acquired a new position in Halozyme Therapeutics in the first quarter valued at about $33,000. Bessemer Group Inc. lifted its position in Halozyme Therapeutics by 62.9% in the first quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company’s stock valued at $34,000 after buying an additional 207 shares during the last quarter. Finally, Employees Retirement System of Texas acquired a new position in Halozyme Therapeutics in the second quarter valued at about $34,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Trading Up 0.2%

Shares of HALO opened at $67.03 on Wednesday. Halozyme Therapeutics has a 52-week low of $42.01 and a 52-week high of $79.50. The company has a quick ratio of 7.01, a current ratio of 8.36 and a debt-to-equity ratio of 4.54. The firm’s fifty day moving average is $71.56 and its two-hundred day moving average is $62.10. The stock has a market cap of $7.84 billion, a PE ratio of 15.34, a price-to-earnings-growth ratio of 0.36 and a beta of 1.16.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.23 by $0.31. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The company had revenue of $325.72 million for the quarter, compared to analysts’ expectations of $282.66 million. During the same quarter in the previous year, the company posted $0.91 EPS. The firm’s quarterly revenue was up 40.8% on a year-over-year basis. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. Research analysts forecast that Halozyme Therapeutics will post 4.73 earnings per share for the current fiscal year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.